- Title
- T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
- Creators
- Alison J. Moskowitz - Memorial Sloan Kettering Cancer CenterGunjan Shah - Memorial Sloan Kettering Cancer CenterHeiko Schöder - Memorial Sloan Kettering Cancer CenterNivetha Ganesan - Memorial Sloan Kettering Cancer CenterHelen Hancock - Memorial Sloan Kettering Cancer CenterTheresa Davey - Memorial Sloan Kettering Cancer CenterLeslie Perez - Memorial Sloan Kettering Cancer CenterSamia Sohail - Memorial Sloan Kettering Cancer CenterAlayna Santarosa - Memorial Sloan Kettering Cancer CenterCharisse Capadona - Memorial Sloan Kettering Cancer CenterBrittney Munayirji - Memorial Sloan Kettering Cancer CenterAnita Kumar - Memorial Sloan Kettering Cancer CenterOscar Lahoud - Memorial Sloan Kettering Cancer CenterConnie Batlevi - Memorial Sloan Kettering Cancer CenterPaul Hamlin - Memorial Sloan Kettering Cancer CenterDavid J. Straus - Memorial Sloan Kettering Cancer CenterColette Owens - Memorial Sloan Kettering Cancer CenterPhilip Caron - Memorial Sloan Kettering Cancer CenterAndrew Intlekofer - Memorial Sloan Kettering Cancer CenterAudrey Hamilton - Memorial Sloan Kettering Cancer CenterSteven Horwitz - Memorial Sloan Kettering Cancer CenterLorenzo Falchi - Memorial Sloan Kettering Cancer CenterWilliam Johnson - Memorial Sloan Kettering Cancer CenterLia Palomba - Memorial Sloan Kettering Cancer CenterAriela Noy - Memorial Sloan Kettering Cancer CenterMatthew Matasar - Memorial Sloan Kettering Cancer CenterGeorgios Pongas - University of Miami Health SystemGilles Salles - Memorial Sloan Kettering Cancer CenterSantosha Vardhana - Memorial Sloan Kettering Cancer CenterBeatriz Wills Sanin - Memorial Sloan Kettering Cancer CenterJoachim Yahalom - Memorial Sloan Kettering Cancer CenterAhmet Dogan - Memorial Sloan Kettering Cancer CenterAndrew Zelenetz - Memorial Sloan Kettering Cancer CenterCraig H. Moskowitz - University of Miami Health System
- Publication Details
- HemaSphere, Vol.6(Suppl), pp.45-46
- Publisher
- Lippincott Williams & Wilkins
- Academic Unit
- Miller School of Medicine; UMMG Department of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- Record Identifier
- 991031785761002976
Journal article
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
HemaSphere, Vol.6(Suppl), pp.45-46
2022-10-03
Metrics
25 Record Views